Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Regulator To “Streamline” Switch Approach With Guidance

This article was originally published in The Tan Sheet

Executive Summary

U.K.’s health authority issued guidance that industry representatives say will help cut months off the time to reclassify a prescription drug to nonprescription, Pharmacy sale. OTC trade group emphasizes the guideline calls for more engagement before firms submit applications.

You may also be interested in...



European OTC Switch Still Muted By Regulatory Resistance

OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.

Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Subtracting Rx Adds To Perrigo OTC Pipeline

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel